

Roman Yatsyshyn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7785227/publications.pdf>

Version: 2024-02-01

11
papers

524
citations

1307594

7
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

736
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. <i>Rheumatology</i> , 2021, 60, 2277-2287.	1.9	36
2	Challenges in diagnosis of limited granulomatosis with polyangiitis. <i>Rheumatology International</i> , 2021, 41, 1337-1345.	3.0	5
3	COVID-19 from a rheumatology perspective: bibliometric and altmetric analysis. <i>Rheumatology International</i> , 2021, 41, 2091-2103.	3.0	8
4	Rheumatology in Ukraine. <i>Rheumatology International</i> , 2020, 40, 175-182.	3.0	6
5	Pulmonary involvement in systemic sclerosis: exploring cellular, genetic and epigenetic mechanisms. <i>Rheumatology International</i> , 2020, 40, 1555-1569.	3.0	11
6	Prostate involvement in granulomatosis with polyangiitis. <i>Rheumatology International</i> , 2019, 39, 1269-1277.	3.0	8
7	SAT0170â€¦A NOVEL FORMULATION OF CT-P13 FOR SUBCUTANEOUS ADMINISTRATION: 30 WEEK RESULTS FROM A PART 2 OF PHASE I/III RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
8	Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 234-240.	0.9	107
9	A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 58-64.	0.9	146
10	Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. <i>Rheumatology</i> , 2017, 56, 1771-1779.	1.9	49
11	A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. <i>Arthritis Research and Therapy</i> , 2016, 18, 82.	3.5	148